A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
Sadhna Shankar(Children's National), Jim Vasselli(MacroGenics (United States)), Paul A. Moore(Zymeworks (Canada)), James Strauss(Texas Oncology), Syd Johnson(MacroGenics (United States)), Liqin Liu(Xinjiang Agricultural University), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Ross La Motte‐Mohs(MacroGenics (United States)), Tony T. Wu(Kaohsiung Veterans General Hospital), Alexander I. Spira(Virginia Cancer Specialists), Ezio Bonvini(MacroGenics (United States))
Cited by 18
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k